Literature DB >> 2139107

Definition of adenovirus type 5 functions involved in the induction of chromosomal aberrations in human cells.

D Caporossi1, S Bacchetti.   

Abstract

Infection of human embryonic kidney cells with adenovirus type 5 (Ad5) induces aberrations (gaps and breaks) in the cell chromosomes. We have conducted a study utilizing a large number of Ad5 mutants to identify the viral functions that are responsible for the occurrence of cytogenetic damage. The results of our investigation have indicated that expression of the gene products of the Ad5 early region 1A (E1A) is necessary for the induction of chromosomal aberrations and that other early viral gene products do not appear to contribute to this phenotype. We have also shown that expression of both the major E1A gene products, the 243 amino acid and the 289 amino acid proteins, is required for induction of damage at wild-type levels, although the 289 amino acid protein appears to retain detectable activity on its own. Lastly, we have observed that deletions in the amino-terminal region of the E1A proteins and in the transactivating domain of the 289 amino acid protein prevent the occurrence of cytogenetic damage, whereas mutations elsewhere in the proteins do not affect this process.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2139107     DOI: 10.1099/0022-1317-71-4-801

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  15 in total

1.  "Hit-and-run" transformation by adenovirus oncogenes.

Authors:  M Nevels; B Täuber; T Spruss; H Wolf; T Dobner
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP.

Authors:  A L Kung; V I Rebel; R T Bronson; L E Ch'ng; C A Sieff; D M Livingston; T P Yao
Journal:  Genes Dev       Date:  2000-02-01       Impact factor: 11.361

3.  Database of mutations within the adenovirus 5 E1A oncogene.

Authors:  J S Mymryk
Journal:  Nucleic Acids Res       Date:  1998-01-01       Impact factor: 16.971

4.  Activation of RNA polymerase III transcription of human Alu repetitive elements by adenovirus type 5: requirement for the E1b 58-kilodalton protein and the products of E4 open reading frames 3 and 6.

Authors:  B Panning; J R Smiley
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

5.  Induction of the cell cycle in baby rat kidney cells by adenovirus type 5 E1A in the absence of E1B and a possible influence of p53.

Authors:  S E Shepherd; J A Howe; J S Mymryk; S T Bayley
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

6.  The transcriptionally competent U2 gene is necessary and sufficient for adenovirus type 12 induction of the fragile site at 17q21-22.

Authors:  S Gargano; P Wang; E Rusanganwa; S Bacchetti
Journal:  Mol Cell Biol       Date:  1995-11       Impact factor: 4.272

7.  Mislocalization of the MRN complex prevents ATR signaling during adenovirus infection.

Authors:  Christian T Carson; Nicole I Orazio; Darwin V Lee; Junghae Suh; Simon Bekker-Jensen; Felipe D Araujo; Seema S Lakdawala; Caroline E Lilley; Jiri Bartek; Jiri Lukas; Matthew D Weitzman
Journal:  EMBO J       Date:  2009-02-05       Impact factor: 11.598

8.  Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells.

Authors:  Claire M Connell; Atsushi Shibata; Laura A Tookman; Kyra M Archibald; Magdalena B Flak; Katrina J Pirlo; Michelle Lockley; Sally P Wheatley; Iain A McNeish
Journal:  J Clin Invest       Date:  2011-03-07       Impact factor: 14.808

Review 9.  Roles for the coactivators CBP and p300 and the APC/C E3 ubiquitin ligase in E1A-dependent cell transformation.

Authors:  A S Turnell; J S Mymryk
Journal:  Br J Cancer       Date:  2006-08-01       Impact factor: 7.640

Review 10.  Strategies for immortalization of primary hepatocytes.

Authors:  Eva Ramboer; Bram De Craene; Joery De Kock; Tamara Vanhaecke; Geert Berx; Vera Rogiers; Mathieu Vinken
Journal:  J Hepatol       Date:  2014-06-06       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.